Literature DB >> 27438510

Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.

Louisa Mezache1, Cynthia Magro, Craig Hofmeister, Flavia Pichiorri, Douglas Sborov, Gerard J Nuovo.   

Abstract

Programmed death-ligand 1 (PD-L1) can reduce the immune response by inhibiting CD8 T-cell proliferation and cytotoxic activity. We studied a series of human viral (molloscum, human papillomavirus, herpes simplex, cytomegalovirus, Epstein-Barr virus, smallpox) and bacterial infections (Helicobacter pylori) for the in situ expression of PD-L1, mononuclear cell infiltration, and CD8 activity and compared this to noninfectious idiopathic inflammatory conditions to better define which immune responses may be more highly correlated with an infectious agent. Each viral and bacterial infection showed an increased PD-L1 expression that was most prominent in the mononuclear cell/CD8+ infiltrate surrounding the infection. However, the CD8 cells were mostly quiescent as evidenced by the low Ki67 index and minimal granzyme expression. Using a melanoma mouse model, acute reovirus infection increased PD-L1 expression, but decreased CD8 cytotoxic activity and Treg (FOXP3) cell numbers. In comparison, idiopathic noninfectious chronic inflammatory processes including lichen sclerosis, eczema, Sjogren's disease, and ulcerative colitis showed a comparable strong PD-L1 expression in the mononuclear cell infiltrates but much greater Treg infiltration. However, this strong immunosuppressor profile was ineffective as evidenced by strong CD8 proliferation and granzyme expression. These data suggest that viral and bacterial infections induce a PD-L1 response that, unlike noninfectious chronic inflammatory conditions, dampens the activity of the recruited CD8 cells which, in turn, may enhance the ability of anti-PD-L1 therapy to eliminate the infectious agent.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27438510      PMCID: PMC5247427          DOI: 10.1097/PAI.0000000000000298

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  30 in total

Review 1.  The PD-1/PD-L1 pathway in human pathology.

Authors:  M Saresella; V Rainone; N M Al-Daghri; M Clerici; D Trabattoni
Journal:  Curr Mol Med       Date:  2012-03       Impact factor: 2.222

2.  PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.

Authors:  Holly Maier; Masanori Isogawa; Gordon J Freeman; Francis V Chisari
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

3.  Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis.

Authors:  Qi T Yu; Masayuki Saruta; Armine Avanesyan; Phillip R Fleshner; Alison H Banham; Konstantinos A Papadakis
Journal:  Inflamm Bowel Dis       Date:  2007-02       Impact factor: 5.325

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 5.  Therapeutic intervention in cancer and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 interaction.

Authors:  Priya Sakthivel; Marcus Gereke; Dunja Bruder
Journal:  Rev Recent Clin Trials       Date:  2012-02

Review 6.  Coinhibitory molecules in cancer biology and therapy.

Authors:  Simone Mocellin; Clara Benna; Pierluigi Pilati
Journal:  Cytokine Growth Factor Rev       Date:  2013-02-04       Impact factor: 7.638

7.  Reduction of natural killer but not effector CD8 T lymphocytes in three consecutive cases of severe/lethal H1N1/09 influenza A virus infection.

Authors:  Laura Denney; Celia Aitken; Chris Ka-Fai Li; Eleri Wilson-Davies; Wai Ling Kok; Colin Clelland; Kevin Rooney; Duncan Young; Tao Dong; Andrew J McMichael; William F Carman; Ling-Pei Ho
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

Review 8.  Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention.

Authors:  Roland S Liblau; F Susan Wong; Lennart T Mars; Pere Santamaria
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

Review 9.  Role of PD-L1/PD-1 in the immune response to respiratory viral infections.

Authors:  Mihnea Tudor Zdrenghea; Sebastian Lennox Johnston
Journal:  Microbes Infect       Date:  2012-01-18       Impact factor: 2.700

10.  Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.

Authors:  Jia Liu; Ejuan Zhang; Zhiyong Ma; Weimin Wu; Anna Kosinska; Xiaoyong Zhang; Inga Möller; Pia Seiz; Dieter Glebe; Baoju Wang; Dongliang Yang; Mengji Lu; Michael Roggendorf
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

View more
  6 in total

1.  PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.

Authors:  Bastian Czogalla; Deborah Pham; Fabian Trillsch; Miriam Rottmann; Julia Gallwas; Alexander Burges; Sven Mahner; Thomas Kirchner; Udo Jeschke; Doris Mayr; Elisa Schmoeckel
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-05       Impact factor: 4.553

Review 2.  Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation.

Authors:  Marina Chulkina; Ellen J Beswick; Irina V Pinchuk
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

Review 3.  Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases.

Authors:  Amke C Beenen; Tatjana Sauerer; Niels Schaft; Jan Dörrie
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

4.  RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue.

Authors:  Kobe Reynders; Els Wauters; Matthieu Moisse; Herbert Decaluwé; Paul De Leyn; Stéphanie Peeters; Maarten Lambrecht; Kristiaan Nackaerts; Christophe Dooms; Wim Janssens; Johan Vansteenkiste; Diether Lambrechts; Dirk De Ruysscher
Journal:  Radiat Oncol       Date:  2018-07-17       Impact factor: 3.481

5.  JAK Inhibitors and Oxidative Stress Control.

Authors:  Amandine Charras; Pinelopi Arvaniti; Christelle Le Dantec; George N Dalekos; Kaliopi Zachou; Anne Bordron; Yves Renaudineau
Journal:  Front Immunol       Date:  2019-12-06       Impact factor: 7.561

Review 6.  Bacterial-Viral Interactions in Human Orodigestive and Female Genital Tract Cancers: A Summary of Epidemiologic and Laboratory Evidence.

Authors:  Ikuko Kato; Jilei Zhang; Jun Sun
Journal:  Cancers (Basel)       Date:  2022-01-15       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.